ROMOSOZUMAB

Course overview

ROMOSOZUMAB IS AN INJECTABLE MEDICATION USED IN THE TREATMENT OF OSTEOPOROSIS IN WOMEN. ROMOSOZUMAB IS AN FDA-APPROVED HUMANIZED MONOCLONAL ANTIBODY SCLEROSTIN INHIBITOR USED TO TREAT OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK OF FRACTURE, INCLUDING PATIENTS WITH A HISTORY OF OSTEOPOROTIC FRACTURE, MULTIPLE RISK FACTORS, OR THAT HAVE FAILED OR ARE INTOLERANT TO OTHER AVAILABLE OSTEOPOROSIS THERAPIES. ROMOSOZUMAB IS THE FIRST ANABOLIC MEDICATION THAT INCREASES BONE FORMATION AND DECREASES BONE RESORPTION. THIS ACTIVITY DESCRIBES THE INDICATIONS, ADMINISTRATION, AND CONTRAINDICATIONS FOR ROMOSOZUMAB AS A VALUABLE AGENT IN THE MANAGEMENT OF OSTEOPOROSIS. THIS ACTIVITY WILL DETAIL THE MECHANISM OF ACTION OF ROMOSOZUMAB AT A MOLECULAR LEVEL AND ITS ADVERSE EVENT PROFILE AND REVIEWS IMPORTANT CONSIDERATIONS PERTINENT FOR HEALTHCARE TEAM MEMBERS IN THE MANAGEMENT OF PATIENTS WITH OSTEOPOROSIS.